Viking Therapeutics, Inc. (VKTX)
| Market Cap | 499.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.50M |
| Shares Out | 72.60M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $6.74 |
| Previous Close | $6.88 |
| Change ($) | -0.14 |
| Change (%) | -2.03% |
| Day's Open | 6.97 |
| Day's Range | 6.62 - 7.05 |
| Day's Volume | 1,153,719 |
| 52-Week Range | 3.26 - 10.09 |
SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabo...
SAN DIEGO, Jan. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabo...
The entire NASH space was shaken by Genfit's trial fiasco; Viking has its own problems. The drug may actually be a wonderful new therapy for NASH/NAFLD patients; however, whether VKTX will ben...
Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metab...
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.
SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.
SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.
SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.
The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.
Viking Therapeutics, Inc.'s (VKTX) CEO Brian Lian on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO, July 29, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabol...
SAN DIEGO, July 22, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metab...
The risk of investing in Viking Therapeutics Inc. (NASDAQ:VKTX) may not be worth the potential rewards, according to a December article in Equities News.
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Friday. BMO Capital initiated coverage on the stock with an Outperform rating and a price target of $14 per share.
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Tuesday, after Chardan initiated coverage on the company's stock with a Buy rating and $15 price target.
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2020 Results - Earnings Call Transcript
The small-cap pharma stock didn't stand a chance in the broader market volatility.
Healthcare bargain hunters can find good values in quality low-priced stocks.
These clinical-stage drugmakers could be a steal at current levels.
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2019 Results - Earnings Call Transcript
Targeting a large and growing disease state, this drug developer's stock requires patience to reap future rewards.
One reason that investors continue to do business with full-service brokerage firms is they generate researched and studied investment ideas.
HOOKIPA Pharma and Viking Therapeutics could catch first at some point this year. Here's why.
The S&P 500 closed out 2019 with another strong month in December. However, analysts remain optimistic on some top stocks heading into 2020.
Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.
Can the stock march even higher after its recent rally?
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2019 Results - Earnings Call Transcript
While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
VKTX produced strong data in reducing liver fat in NAFLD patients.
This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower pr...
It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?
Viking Therapeutics' (VKTX) CEO Brian Lian on Q2 2019 Results - Earnings Call Transcript
The catalysts these companies enjoy could translate into big returns for shareholders in the coming decades.
They're risky. You'll have to wait years before any significant revenue comes in.
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2019 Results - Earnings Call Transcript
Viking's shares received a boost from a pair of catalysts last month.
Bargain hunting? These out-of-favor biotech and e-commerce stocks should appeal to value investors.
Investors were impressed with updated results for the company's lead candidate.
About VKTX
Viking Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more...]
| Industry Biotechnology | IPO Date Apr 29, 2015 |
| CEO Brian Lian | Employees 18 |
| Stock Exchange NASDAQ | Ticker Symbol VKTX |
Analyst Forecasts
According to 14 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is 19.71, which is an increase of 192.43% from the latest price.